A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration

Nature Reviews Neuroscience

Volumn 17, Issue 4, 2016, Pages 251-260

  Walsh, Dominic M ^a   Selkoe, Dennis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[25-35]; NEUROTOXIN; PRION PROTEIN; PROTEIN; PROTEIN AGGREGATE; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN REGION; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; IATROGENIC CREUTZFELDT JAKOB DISEASE; IATROGENIC DISEASE; LEWY BODY; NERVE CELL; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SPREADING; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; REVIEW; ANIMAL; COMPLICATION; METABOLISM; PATHOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN TRANSPORT;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN TRANSPORT; TAU PROTEINS;

EID: 84962081972     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn.2016.13     Document Type: Review

References (147)

1. Selkoe, D. J. Folding proteins in fatal ways. Nature 426, 900-904 (2003).
2. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49-60 (2003).
3. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
4. Prusiner, S. B. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336, 1511-1513 (2012).
5. Frost, B. and Diamond, M. I. Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 11, 155-159 (2010).
6. Brettschneider, J., Del Tredici, K., Lee, V. M. and Trojanowski, J. Q. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci. 16, 109-120 (2015).
7. Glenner, G. G. Amyloid deposits and amyloidosis. The β-fibrilloses (first of two parts). N. Engl. J. Med. 302, 1283-1292 (1980).
8. Jarrett, J. T. and Lansbury, P. T. Jr. Seeding "onedimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimers disease and scrapie? Cell 73, 1055-1058 (1993).
9. Walsh, D. M. and Selkoe, D. J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11, 213-228 (2004).
10. Braak, H. et al. Staging of brain pathology related to sporadic Parkinsons disease. Neurobiol. Aging 24, 197-211 (2003).
11. Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. and Del Tredici, K. Staging of Alzheimer diseaseassociated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389-404 (2006).
12. Brundin, P., Melki, R. and Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11, 301-307 (2010).
13. Guest, W. C. et al. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. J. Toxicol. Environ. Health A 74, 1433-1459 (2011).
14. Aguzzi, A. Cell biology: beyond the prion principle. Nature 459, 924-925 (2009).
15. Ashe, K. H. and Aguzzi, A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 7, 55-59 (2013).
16. Mattson, M. P. and Magnus, T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7, 278-294 (2006).
17. Jackson, W. S. Selective vulnerability to neurodegenerative disease: the curious case of prion protein. Dis. Model. Mech. 7, 21-29 (2014).
18. Petersen, R. B., Parchi, P., Richardson, S. L., Urig, C. B. and Gambetti, P. Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. J. Biol. Chem. 271, 12661-12668 (1996).
19. Gambetti, P., Kong, Q., Zou, W., Parchi, P. and Chen, S. G. Sporadic and familial CJD: classification and characterisation. Br. Med. Bull. 66, 213-239 (2003).
20. Kimberlin, R. H., Hall, S. M. and Walker, C. A. Pathogenesis of mouse scrapie. Evidence for direct neural spread of infection to the CNS after injection of sciatic nerve. J. Neurol. Sci. 61, 315-325 (1983).
21. Scott, J. R. and Fraser, H. Transport and targeting of scrapie infectivity and pathology in the optic nerve projections following intraocular infection. Prog. Clin. Biol. Res. 317, 645-652 (1989).
22. Yoshiyama, Y., Lee, V. M. and Trojanowski, J. Q. Frontotemporal dementia and tauopathy. Curr. Neurol. Neurosci. Rep. 1, 413-421 (2001).
23. Hansen, L. A., Masliah, E., Galasko, D. and Terry, R. D. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J. Neuropathol. Exp. Neurol. 52, 648-654 (1993).
24. Braak, H. and Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
25. Avila, J., Lucas, J. J., Perez, M. and Hernandez, F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384 (2004).
26. Braak, H. and Del Tredici, K. The pathological process underlying Alzheimers disease in individuals under thirty. Acta Neuropathol. 121, 171-181 (2011).
27. Jellinger, K. A. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 116, 1-16 (2008).
28. Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613-634 (2009).
29. Farrer, M. et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293-300 (2001).
30. Takahashi, H. et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44, 437-441 (1994).
31. van de Warrenburg, B. P. et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555-557 (2001).
32. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. and Olanow, C. W. Lewy body-like pathology in longterm embryonic nigral transplants in Parkinsons disease. Nat. Med. 14, 504-506 (2008).
33. Brundin, P. and Kordower, J. H. Neuropathology in transplants in Parkinsons disease: implications for disease pathogenesis and the future of cell therapy. Prog. Brain Res. 200, 221-241 (2012).
34. Ahn, T. B., Langston, J. W., Aachi, V. R. and Dickson, D. W. Relationship of neighboring tissue and gliosis to a-synuclein pathology in a fetal transplant for Parkinsons disease. Am. J. Neurodegener. Dis. 1, 49-59 (2012).
35. Cooper, O. et al. Lack of functional relevance of isolated cell damage in transplants of Parkinsons disease patients. J. Neurol. 256 (Suppl. 3), 310-316 (2009).
36. Hallett, P. J. et al. Long-term health of dopaminergic neuron transplants in Parkinsons disease patients. Cell Rep. 7, 1755-1761 (2014).
37. Barker, R. A., Barrett, J., Mason, S. L. and Bjrklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinsons disease. Lancet Neurol. 12, 84-91 (2013).
38. de Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimers disease. Neuron 73, 685-697 (2012).
39. Liu, L. et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302 (2012).
40. Yetman, M. J., Lillehaug, S., Bjaalie, J. G., Leergaard, T. B. and Jankowsky, J. L. Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex. Brain Struct. Funct. http://dx.doi.org/10.1007/s00429-015-1040-9 (2015).
41. Jucker, M. and Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51 (2013).
42. Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913 (2009).
43. Clavaguera, F. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. USA 110, 9535-9540 (2013).
44. Stancu, I. C. et al. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Acta Neuropathol. 129, 875-894 (2015).
45. Ridley, R. M., Baker, H. F., Windle, C. P. and Cummings, R. M. Very long term studies of the seeding of beta-amyloidosis in primates. J. Neural Transm. 113, 1243-1251 (2006).
46. Luk, K. C. et al. Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
47. Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger a-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351-362 (2014).
48. Terry, R. D. Do neuronal inclusions kill the cell? J. Neural Transm. Suppl. 59, 91-93 (2000).
49. Caughey, B. and Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
50. Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005).
51. Berger, Z. et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650-3662 (2007).
52. Wegmann, S. et al. Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J. 34, 3028-3041 (2015).
53. Benilova, I., Karran, E. and De Strooper, B. The toxic Aβ oligomer and Alzheimers disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
54. Blennow, K. et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231-245 (1995).
55. Motter, R. et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimers disease. Ann. Neurol. 38, 643-648 (1995).
56. Hawkes, C. H., Del Tredici, K. and Braak, H. Parkinsons disease: the dual hit theory revisited. Ann. NY Acad. Sci. 1170, 615-622 (2009).
57. Barten, D. M. et al. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J. Alzheimers Dis. 24 (Suppl. 2), 127-141 (2011).
58. Chai, X., Dage, J. L. and Citron, M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis. 48, 356-366 (2012).
59. Mably, A. J. et al. Tau immunization: a cautionary tale? Neurobiol. Aging 36, 1316-1332 (2015).
60. Zetterberg, H. et al. Plasma tau levels in Alzheimers disease. Alzheimers Res. Ther. 5, 9 (2013).
61. Borghi, R. et al. Full length a-synuclein is present in cerebrospinal fluid from Parkinsons disease and normal subjects. Neurosci. Lett. 287, 65-67 (2000).
62. El-Agnaf, O. M. et al. a-synuclein implicated in Parkinsons disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945-1947 (2003).
63. Mollenhauer, B. et al. a-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240 (2011).
64. Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alphasynuclein transgenic model of Lewy body disease. PLoS ONE 6, e19338 (2011).
65. Boutajangout, A., Quartermain, D. and Sigurdsson, E. M. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30, 16559-16566 (2010).
66. Holmes, B. B. et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA 110, E3138-E3147 (2013).
67. Caughey, B. and Baron, G. S. Prions and their partners in crime. Nature 443, 803-810 (2006).
68. Borchelt, D. R., Rogers, M., Stahl, N., Telling, G. and Prusiner, S. B. Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. Glycobiology 3, 319-329 (1993).
69. Harris, D. A. et al. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 32, 1009-1016 (1993).
70. Altmeppen, H. C. et al. Proteolytic processing of the prion protein in health and disease. Am. J. Neurodegener Dis. 1, 15-31 (2012).
71. Halliday, M., Radford, H. and Mallucci, G. R. Prions: generation and spread versus neurotoxicity. J. Biol. Chem. 289, 19862-19868 (2014).
72. Sandberg, M. K. et al. Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nat. Commun. 5, 4347 (2014).
73. Chiesa, R. and Harris, D. A. Prion diseases: what is the neurotoxic molecule? Neurobiol. Dis. 8, 743-763 (2001).
74. Solomon, I. H., Schepker, J. A. and Harris, D. A. Prion neurotoxicity: insights from prion protein mutants. Curr. Issues Mol. Biol. 12, 51-61 (2010).
75. Collinge, J. and Clarke, A. R. A general model of prion strains and their pathogenicity. Science 318, 930-936 (2007).
76. Holmqvist, S. et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805-820 (2014).
77. Wakabayashi, K., Takahashi, H., Ohama, E. and Ikuta, F. Parkinsons disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 79, 581-583 (1990).
78. Hawkes, C. H., Shephard, B. C. and Daniel, S. E. Is Parkinsons disease a primary olfactory disorder? QJM 92, 473-480 (1999).
79. Wang, N., Gibbons, C. H., Lafo, J. and Freeman, R. a-Synuclein in cutaneous autonomic nerves. Neurology 81, 1604-1610 (2013).
80. Lemere, C. A. et al. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16-32 (1996).
81. Frost, B., Ollesch, J., Wille, H. and Diamond, M. I. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J. Biol. Chem. 284, 3546-3551 (2009).
82. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of a-synuclein. Proc. Natl Acad. Sci. USA 106, 13010-13015 (2009).
83. Watts, J. C. et al. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl Acad. Sci. USA 110, 19555-19560 (2013).
84. Guo, J. L. and Lee, V. M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130-138 (2014).
85. Mirbaha, H., Holmes, B. B., Sanders, D. W., Bieschke, J. and Diamond, M. I. Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J. Biol. Chem. 290, 14893-14903 (2015).
86. Usenovic, M. et al. Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. J. Neurosci. 35, 14234-14250 (2015).
87. Brown, P. et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55, 1075-1081 (2000).
88. Wroe, S. J. et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368, 2061-2067 (2006).
89. Collinge, J. Variant Creutzfeldt-Jakob disease. Lancet 354, 317-323 (1999).
90. Will, R. G. et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-925 (1996).
91. Beekes, M., Thomzig, A., Schulz-Schaeffer, W. J. and Burger, R. Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? Acta Neuropathol. 128, 463-476 (2014).
92. Irwin D. J. et al. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 70, 462-468 (2013).
93. Goudsmit, J. et al. Evidence for and against the transmissibility of Alzheimer disease. Neurology 30, 945-950 (1980).
94. Godec, M. S. et al. Evidence against the transmissibility of Alzheimers disease. Neurology 41, 1320 (1991).
95. Brown, P. et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. 35, 513-529 (1994).
96. Baker, H. F., Ridley, R. M., Duchen, L. W., Crow, T. J. and Bruton, C. J. Induction of beta (A4)-amyloid in primates by injection of Alzheimers disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol. Neurobiol. 8, 25-39 (1994).
97. Baker, H. F., Ridley, R. M., Duchen, L. W., Crow, T. J. and Bruton, C. J. Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int. J. Exp. Pathol. 74, 441-454 (1993).
98. Rewcastle, N., Gibbs, C. J. and Gajdusek, D. Transmission of familial Alzheimers disease to primates. J. Neuropathol. Exp. Neurol. 37, 679 (1978).
99. Viola, K. L. et al. Towards non-invasive diagnostic imaging of early-stage Alzheimers disease. Nat. Nanotechnol. 10, 91-98 (2015).
100. Moreno, J. A. et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prioninfected mice. Sci. Transl. Med. 5, 206ra138 (2013).
101. Greig, J. R. Scrapie: observations on the transmission of the disease by mediate contact. Veterinary J. 96, 203-206 (1940).
102. Cuille, J. and Chelle, P. L. Investigations of scrapie in sheep. Veterinary Med. 34, 417 (1939).
103. Chandler, R. L. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet 1, 1378-1379 (1961).
104. Hadlow, W. J. Scrapie and kuru. Lancet 274, 289-290 (1959).
105. Gajdusek, D. C., Gibbs, C. J. and Alpers, M. Experimental transmission of a Kuru-like syndrome to chimpanzees. Nature 209, 794-796 (1966).
106. Klatzo, I., Gajdusek, D. C. and Zigas, V. Pathology of Kuru. Lab. Invest. 8, 799-847 (1959).
107. Gibbs, C. J. Jr et al. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161, 388-389 (1968).
108. Griffith, J. S. Self-replication and scrapie. Nature 215, 1043-1044 (1967).
109. Bolton, D. C., McKinley, M. P. and Prusiner, S. B. Identification of a protein that purifies with the scrapie prion. Science 218, 1309-1311 (1982).
110. Oesch, B. et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40, 735-746 (1985).
111. Chesebro, B. et al. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature 315, 331-333 (1985).
112. Hsiao, K. K. et al. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 250, 1587-1590 (1990).
113. Lloyd, S. E., Mead, S. and Collinge, J. Genetics of prion diseases. Curr. Opin. Genet. Dev. 23, 345-351 (2013).
114. Bueler, H. et al. Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-1347 (1993).
115. Come, J. H., Fraser, P. E. and Lansbury, P. T. Jr. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc. Natl Acad. Sci. USA 90, 5959-5963 (1993).
116. Eigen, M. Prionics or the kinetic basis of prion diseases. Biophys. Chem. 63, A1-A18 (1996).
117. Cohen, S. I. et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl Acad. Sci. USA 110, 9758-9763 (2013).
118. Silveira, J. R. et al. The most infectious prion protein particles. Nature 437, 257-261 (2005).
119. Safar, J. et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat. Med. 4, 1157-1165 (1998).
120. Cronier, S. et al. Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochem. J. 416, 297-305 (2008).
121. Sandberg, M. K., Al-Doujaily, H., Sharps, B., Clarke, A. R. and Collinge, J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470, 540-542 (2011).
122. Kane, M. D. et al. Evidence for seeding of β-amyloid by intracerebral infusion of Alzheimer brain extracts in β-amyloid precursor protein-transgenic mice. J. Neurosci. 20, 3606-3611 (2000).
123. Meyer-Luehmann, M. et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006).
124. Rosen, R. F. et al. Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats. J. Neurochem. 120, 660-666 (2012).
125. Stohr, J. et al. Purified and synthetic Alzheimers amyloid beta (Aβ) prions. Proc. Natl Acad. Sci. USA 109, 11025-11030 (2012).
126. Harper, J. D. and Lansbury, P. T. Jr. Models of amyloid seeding in Alzheimers disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407 (1997).
127. Arosio, P., Knowles, T. P. and Linse, S. On the lag phase in amyloid fibril formation. Phys. Chem. Chem. Phys. 17, 7606-7618 (2015).
128. Esparza, T. J. et al. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104-119 (2013).
129. Shankar, G. M. et al. Amyloid-β protein dimers isolated directly from Alzheimers brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
130. Cummings, C. J. et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
131. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. and Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
132. Serrano-Pozo, A. et al. Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology. Brain 133, 1312-1327 (2010).
133. Koffie, R. M. et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012-4017 (2009).
134. Langer, F. et al. Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. J. Neurosci. 31, 14488-14495 (2011).
135. Eisele, Y. S. et al. Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis. Science 330, 980-982 (2010).
136. Jaunmuktane, Z. et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 525, 247-250 (2015).
137. Jaunmuktane, Z. et al. Erratum: Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 526, 595 (2015).
138. Thery, C. et al. Proteomic analysis of dendritic cellderived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166, 7309-7318 (2001).
139. Rustom, A., Saffrich, R., Markovic, I., Walther, P. and Gerdes, H. H. Nanotubular highways for intercellular organelle transport. Science 303, 1007-1010 (2004).
140. Caughey, B., Baron, G. S., Chesebro, B. and Jeffrey, M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu. Rev. Biochem. 78, 177-204 (2009).
141. Hashimoto, M. and Masliah, E. Alpha-synuclein in Lewy body disease and Alzheimers disease. Brain Pathol. 9, 707-720 (1999).
142. Ittner, L. M. et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimers disease mouse models. Cell 142, 387-397 (2010).
143. Zempel, H. et al. Amyloid-β oligomers induce synaptic damage via tau-dependent microtubule severing by TTLL6 and spastin. EMBO J. 32, 2920-2937 (2013).
144. Kanmert, D. et al. C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death. J. Neurosci. 35, 10851-10865 (2015).
145. Cho, Y. et al. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid 22, 175-180 (2015).
146. Dettmer, U. et al. Parkinson-causing a-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun. 6, 7314 (2015).
147. Bartels, T., Choi, J. G. and Selkoe, D. J. a-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110 (2011).